washington  reuters    a u s  house of representatives subcommittee will take up bipartisan legislation next week to foster generic drug development  the committee s chairman  representative greg walden  said on thursday   president  donald  trump made it clear     he wants competition to lower drug prices  and that is precisely what this measure will help accomplish   walden  a republican from oregon  said at a health subcommittee hearing   specifically the bill will require fda  the food and drug administration  to prioritize  expedite and review generic applications of drug products that are currently in shortage  or where there are few manufacturers on the market   walden said  trump this week met pharmaceutical executives and called on them to cut prices  he said the government was paying  astronomical  prices for medicines in its health programs for older  disabled and poor people  walden said recently there had been cases of  bad actors  who  jacked up the price of drugs because there was no competition   but he did not name names   we want to make sure that does not happen again   the congressman said   for those in the industry who think it s okay to corner a market  drive up prices and rip off consumers  know that your days are numbered   walden said  he said the bill would also increase transparency around the backlog of generic drug applications at the fda  saying there was an  unacceptably high  number  the bill will be sponsored by representative gus bilirakis  a republican from florida  and representative kurt schrader  a democrat from oregon  walden said  republicans have the majority in both chambers of congress  